Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

The SEC concluded its investigation and negotiated a $40 million settlement from Cassava Sciences without admitting or ...

Cassava Sciences ( (SAVA)) has provided an announcement ... Amid these advancements, Cassava settled with the SEC, paying a $40 million penalty for inaccurately disclosed information, allowing ...

Cassava Sciences is moving forward with Phase III trials after paying $40m to settle an SEC case alleging misleading data from its Phase IIb trial of simufilam. The US Securities and Exchange ...

Cassava Sciences (NASDAQ:SAVA ... citing a settlement the company recently reached with the SEC. With only Hold ratings from analysts, the fortunes of the Austin, Texas-based biotech have reversed ...

Last month, Cassava Sciences Inc. (NASDAQ:SAVA) agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial ...

Cassava Sciences faced a $40 million penalty to focus on Simufilam's development following SEC charges over misleading trial data. Cassava Sciences completed ReTHINK Phase 3 trial with 804 ...

Last month, Cassava Sciences Inc. (NASDAQ:SAVA) agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial Alzheimer’s ...

Recently, Cassava Sciences (NASDAQ:SAVA) faced scrutiny from the U.S. Securities and Exchange Commission (SEC) regarding ...

SEC Filings provided by EDGAR Online, Inc.